Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two ...
Read Article »Home » Hardman Research
Hardman Research
-
Arbuthnot Banking Group: Acquisition of Asset Alliance
-
Incanthera: Solid progress since listing
-
Arix Bioscience: Artios attracts Merck KGaA in deal up to $7bn
-
Oakley Capital Investments NAV: conservative, robust and with growth upside
-
Urban Logistics REIT: Six months to September 8.0% total asset returns
-
Palace Capital: Interim results on track – upside clear in FY’22
-
Chamberlin: Trading update ‒ main businesses performing solidly
-
Yew Grove REIT: Strong strategy, tenants and total returns
-
Pantheon International Analyst Q&A: NAV resilience through downturns (LON:PIN)
-
Arix Bioscience: Hitting the jackpot
-
Sportech Plc: Bettor technology
-
Non-Standard Finance: 1H’20 results
-
City of London Investment Group: Boost from positive markets and deal completion
-
Tissue Regenix Group: Funded through to profitability
-
Advanced Oncotherapy: Progress towards commissioning of first LIGHT
-
Diurnal Group: And then there were three
-
Chamberlin: Trading update most encouraging
-
Shield Therapeutics: Optimism over US deal
-
Arix Bioscience: Realising the valuation disconnect
-
City of London Investment Group: Solid results, with surprise dividend increase
-
Diurnal Group: Closely watching the regulators
-
Filta Group FOG is lifting
-
Volta Finance: Value added by active portfolio management
-
Surface Transforms A whole new level of contract winning
-
Real Estate Credit Investments: Improving returns on new opportunities
-
MORhomes: Low-risk issuer in a low-risk market
-
Neodecortech: Reassuringly robust
-
ICG Enterprise Trust Defensive growth: explaining downside resilience
-
Artificial Solutions navigating well through the COVID-19 pandemic
-
Oakley Capital Investments “When it rains gold, put out the bucket”
-
Pantheon International 2020 results: positioned for sustained growth
-
Diurnal Group Flow of regulatory approvals
-
Primary Health Properties Strong set of results, confirming ongoing rent rises
-
City of London Investment Group Market recovery boosts FUM
-
Allergy Therapeutics Record sales and a COVID-19 wildcard
-
Palace Capital Encouraging full-year results
-
Non-Standard Finance FY’19 solid; outlook – broad range of outcomes
-
ICG Enterprise Trust Outperformance through every stage of cycle
-
Advanced Oncotherapy funded through to clinical events
-
B-North: Bridge over troubled waters